ARA 290 10 mg vials

ARA-290 is a small peptide derived from the helix beta domain or erythropoietin. EPO has long been know to exhibit actions beyond the stimulation of red blood cell production in bone marrow. The glycoprotein, which is made in the kidney, has been found to stimulate blood vessel growth, promote cell survival, alter blood pressure, and produce neuroprotective effects in diabetic neuropathy. ARA-290 offers the neuroprotective and pain relieving effects of EPO without stimulating red blood cell production. ARA-290 has completed phase II trials and is in preparation to enter phase III trials for a variety of applications in diabetes and the autoimmune sarcoidosis. Right now the peptide is of active interest for its ability to control neuropathic pain, but it is also under investigation as a potential stimulator of wound repair in chronic diabetes, as an immune modulatory peptide, and as a potential treatment for systemic lupus erythematosus.

10mg of ARA290 peptide.

For research purposes only.

ARA 290 (Cibinetide) is generally well-tolerated in clinical trials, with side effects reported as mild, transient, and relatively rare. Because it was engineered specifically to mimic the tissue-protective properties of erythropoietin (EPO) without stimulating red blood cell production, it does not carry the dangerous blood-clotting or blood-pressure risks associated with EPO. [1, 2]

However, because it is an injectable peptide mostly used in research or under specific clinical guidance, several known localized and systemic side effects can occur. [1, 3]

In Phase II clinical trials (such as those for sarcoidosis and diabetic small fiber neuropathy), the most frequently noted side effects include: [4, 5, 6]

• Injection Site Reactions: Mild pain, redness, swelling, itching, or tenderness where the needle punctures the skin (<5% incidence).
• Headaches: Short-lived, mild headaches that typically resolve as the body adapts to the peptide (<2% incidence).
• Gastrointestinal Discomfort: Occasional mild nausea or transient digestive upset (<3% incidence).
• Fatigue or Dizziness: A temporary sense of tiredness or mild lightheadedness shortly after dosing.
• Autonomic Shifts: Some users report subtle, brief changes in blood pressure (such as a slight dip), feeling flushed or warm, or mild heart palpitations right after injection. [2, 3, 7, 8]

While the immediate side-effect profile is modest, using ARA 290 carries significant safety caveats due to its current regulatory and developmental status: [3, 8, 9, 10, 11]

• Lack of Long-Term Safety Data: Most clinical studies on ARA 290 have only evaluated short-term use (typically 4 to 12 weeks). The long-term safety profile of chronic, multi-year use in humans remains unproven. [2, 4]
• Investigational Status: ARA 290 is not broadly FDA-approved. Because commercial pharmaceutical development has historically stalled, much of the ARA 290 available outside official clinical trials comes from unverified peptide suppliers. [1, 9, 12]
• Contamination Risks: Sourcing unregulated research peptides introduces significant secondary risks, such as improper dosing, chemical impurities, or lack of sterility, which can cause severe infections or unpredictable immune reactions. [1, 2, 9]

If you are considering this peptide, are you looking to treat a specific condition like small fiber neuropathy, or do you want to know more about the standard dosages used in clinical trials?